Introduction
Despite the refinement of surgical techniques that have led to a significant reduction in the more common side-effects from radical prostatectomy for the treatment of clinically localized adenocarcinoma of the prostate, a substantially unchanged fraction of patients (15-50%) still experience biochemical relapse after radical surgery. Risk factors for biochemical failure and, often, micrometastatic disease include capsular perforation, seminal vesicle invasion, and positive surgical margins (PSMs).
Adjuvant and salvage radiotherapy (SRT) have a well established role in the management of locally recurrent prostate cancer, but with some limitations. Adjuvant radiotherapy (ART) is unnecessary in more than 30-50% of cases, whereas SRT, on the contrary, may not be curative in up to 90% of inadequately selected patients harboring micrometastatic, but still undetectable, disease.
Adjuvant radiotherapy
Three large, randomized, prospective trials, European Organization for Research and Treatment of Cancer (EORTC) 22911, Southwest Oncology Group (SWOG) 8794 and German ARO 96-02/AUO AP 09/95) that altogether enrolled over 1500 patients compared ART with observation alone after radical prostatectomy. At initial publication, these studies showed the impact of ART on biochemical relapse-free survival (bRFS) and disease-free survival (DFS) but not on overall survival (OS).
A subsequent update of the SWOG trial at 12.6-year follow-up demonstrated a benefit in OS (hazard ratio 0.72, P ¼ 0.023) [1] . It should be noted, however, that one-third of the patients enrolled in the SWOG trial had a persistently detectable prostate-specific antigen (PSA) postoperatively; it may be, therefore, unlikely that this OS benefit would be reproducible in a cohort of high-risk men with undetectable PSA.
Purpose of review
Adjuvant and salvage radiotherapy after radical prostatectomy have an established role in the management of high-risk patients. We discuss contemporary data on optimal timing and doses of radiotherapy, role of hormonal therapy and pelvis irradiation, and toxicity.
Recent findings
Positive surgical margins are not predictive of reduced overall survival, even in patients treated with adjuvant radiotherapy. Salvage irradiation fails to decrease the risk of death. In both adjuvant and salvage settings, radiation doses more than 66-70 Gy result in a significant improvement of biochemical relapse-free survival, whereas hormonal therapy is still of unproven effect. Early referral for salvage radiotherapy might be as effective as adjuvant irradiation, although only less than 50% of patients whose prostate-specific antigen is more than 0.5 ng/ml at referral benefit from salvage radiotherapy. The prophylactic irradiation of pelvic nodal area may have a role in postprostatectomy irradiation owing to the risk of occult lymph-nodal metastases. New radiotherapy techniques lead to a significant reduction in rectal, but not urinary, toxicity. Summary Ongoing Phase III trials will address the role of hormonal therapy and pelvic irradiation in combination with standard dose adjuvant and salvage radiotherapy. In the case of positive results, these findings should be confirmed also in combination with high radiation doses. Just before the publication of these trials, less than 20% of patients with pT3 disease and PSMs received ART, according to the largest pattern of care analysis of the role of ART performed by the Surveillance, Epidemiology and End Results (SEER) Program [2] . Quite surprisingly, even after the presentation (2004) (2005) and publication (2005) (2006) of the two EORTC and SWOG trials, recommendations of ART for men with extracapsular extension and/or PSMs did not increase, possibly because the two studies initially reported only improved bRFs [3 ] . Thus far many urologists, concerned by the possible excessive toxicity of ART delivered to all high-risk patients, regard early SRT as the standard of care [4] .
The possible impact on mortality of PSMs was retrospectively analyzed on a cohort of 11 729 patients who underwent radical prostatectomy at the Mayo Clinic between 1990 and 2006. Overall, 3651 (31%) had positive margins, and 454 (12%) of patients with PSM received ART. After a median follow-up of 8.2 years, on multivariate analysis, the presence of PSM was associated with increased risk of biochemical and local recurrence, and the need for salvage radiation and/or androgen deprivation therapy, but was not a significant predictor of systemic progression, cancer-specific death, or overall mortality. The authors concluded that these results must be considered when evaluating patients for adjuvant treatments, given their potential morbidity and costs.
No prospective randomized trials have investigated the role of ART in node-positive cases. Nevertheless, in a large two-institution retrospective analysis on 703 nodepositive patients, ART emerged as one of the co-variates independently predictive (hazard ratio 0.42, P ¼ 0.0002) of improved cancer-specific survival. The same series indicated that two positive nodes represent a significant cut-off value for cancer-specific survival [5] .
Salvage radiotherapy
In order to assess the impact of SRT after biochemical recurrence (BCR), Boorjian et al. [6 ] retrospectively analyzed a total of 2657 patients who experienced BCR, 856 of whom (32%) received SRT. Median follow-up after BCR was 6.9 years.
At multivariate analysis, patients who received SRT had a significantly reduced risk of local recurrence (À90%, hazard ratio 0.13, P < 0.0001), of late salvage hormonal therapy (À20%, hazard ratio 0.81, P ¼ 0.003), and of systemic progression (À75%, hazard ratio 0.24, P < 0.0001). However, no significant association of SRT with overall mortality was detected (P ¼ 0.85). Moreover, differently from that reported by Trock et al. [7] , no significant association between SRT and OS was evident in patients with PSA doubling time less than 6 months who received SRT within 2 years of BCR.
Song et al. [8] , by retrospectively analyzing a cohort of 121 patients who experienced BCR after radical prostatectomy, concluded that SRT alone or in combination with androgen-deprivation therapy (ADT) significantly increased DFS as compared with ADT alone.
Role of radiotherapy dose
Assuming that the residual tumor burden after prostatectomy would be many logarithms smaller than in the case of radical irradiation, the dose of radiotherapy used in the postoperative setting is generally 20-25% lower (around 60 vs. 76-80 Gy) than that commonly used in the case of radical irradiation.
A subset analysis of the SWOG 8794 study demonstrated that the pattern of failure in high-risk prostate cancer not submitted to ART after radical prostatectomy is predominantly local [9] .
Awareness of the key role of local control after radical prostatectomy raises questions about the issue of the optimal radiotherapy doses to be used in the adjuvant setting.
A retrospective analysis of 334 high-risk, node-negative patients with a median follow-up of 8 years, indicated that both 5-year bRFS and DFS were significantly higher in patients receiving an ART dose of at least 70.2 Gy [10] . The 12% difference in 5-year bRFS observed between two cohorts differing by only 4 Gy in terms of median dose delivered to the prostatic bed (70 vs. 66 Gy) indirectly supported an elegant radiobiological model postulating a 3% gain of 5-year bRFS for every additional Gy delivered in the postoperative setting [11] .
Accordingly, Ost et al. [12] reported an encouraging 93% 3-year bRFS in a cohort of 104 high-risk patients treated Radiation therapy following prostatectomy Cozzarini and Di Muzio 207
Key points
In both adjuvant and salvage setting, radiation doses more than 66-70 Gy result in a significant improvement in biochemical relapse-free survival. Whole pelvis irradiation and hormonal therapy may improve the efficacy of postprostatectomy irradiation owing to the risk of occult lymph-nodal metastases even in patients believed to be node-negative. New radiotherapy techniques, such as intensitymodulated radiotherapy and helical tomotherapy, lead to significant reduction in rectal, but not urinary, toxicity.
with high-dose (median 74 Gy) adjuvant intensity-modulated radiotherapy (IMRT).
The researchers of the Mayo Clinic reported a 39% 5-year risk of BCR in patients receiving a SRT dose more than 66.6 Gy, as compared to 46 and 57% in patients treated at 64.8-66.6 and less than 64.8 Gy, respectively (relative risk 0.70, P ¼ 0.002) [13] .
Adjuvant vs. salvage radiotherapy
No randomized, prospective trial has addressed the issue of the potential superiority or equivalence of ART relative to SRT.
Ost et al. [14 ] performed an elegant matched control analysis on 278 patients treated with high-dose intensitymodulated ART (n ¼ 144, median dose 74 Gy) or SRT (n ¼ 134, median dose 76 Gy). After the matching procedure, a total of 178 patients were analyzed (89 : 89). After a median follow-up of 36 months, a significant benefit in terms of 3-year bRFS favoring the ART group (90 vs. 65%, P ¼ 0.002) was evident. A subsequent subset analysis indicated that patients with PSA less than 0.5 ng/ml at referral for SRT fared significantly better (3-year bRFS: 86 vs. 46%, P < 0.001) than those with higher preradiotherapy PSA values. On the contrary, no significant difference in terms of risk of biochemical failure was evident between patients treated with ART or with early (PSA at referral <0.5 ng/ml) SRT (92 vs. 86%, respectively, P ¼ 0.67).
The authors concluded that an early referral for SRT might be as effective as ART when doses more than 70 Gy are applied, whereas SRT, even at high doses, is unable to prevent biochemical failure in over 50% of patients with PSA values at referral at least 0.5 ng/ml.
Hormonal therapy and postoperative radiotherapy
To date, it is unclear whether the addition of hormonal therapy, either neoadjuvant or adjuvant to postoperative irradiation, may translate into a clinically significant benefit.
Choo et al. [15, 16] reported on two single-arm, prospective pilot studies evaluating the toxicity profile and the efficacy of a combined modality treatment consisting of 2-year androgen suppression in addition to ART [15] or SRT [16] .
Four Radiation Oncology Departments located in the USA, Canada, and New Zealand participated in the two trials, which enrolled 75 and 78 patients in the ART and SRT protocol, respectively. The median dose delivered to the prostatic bed in the ART study was 60 Gy in the case of undetectable postoperative PSA and 66 Gy in patients whose postoperative PSA was at least 0.20 ng/ml [15] . In the SRT arm, the median dose planned to the prostatic bed was 66 Gy [16] .
After a median follow-up of 6.4 years, 5-year and 7-year relapse-free survival reached the encouraging values of 94.4 and 86.3% in the ART cohort, and 91.5 and 78.6% in the SRT group, respectively.
Both EORTC and RTOG are conducting large phase III trials aimed at confirming the promising results derived from the above-mentioned pilot studies and from a few retrospective small-sized series. The EORTC 22043-30041 trial is investigating the possible clinical benefit deriving from the addition of 6 months of bicalutamide 150 mg daily to ART, whereas in the RTOG 0534 trial, the role of neoadjuvant and adjuvant short-term androgen deprivation and of whole-pelvis irradiation [whole-pelvis radiotherapy (WPRT)] in conjunction to SRT are being tested.
The radiotherapy doses planned in the EORTC and RTOG trial are 64 Gy and 64.8-70.2 Gy, respectively. Should these two studies indicate the superiority of combined modality treatment over radiation therapy alone, one question will remain unanswered: could the same benefit in terms of reduced risk of clinical failure be expected from the addition of hormonal therapy to highdose postoperative radiotherapy?
In the radical setting, Krauss et al. [17] recently reported the lack of benefit in any clinical endpoint (freedom from biochemical, local, distant recurrence or overall or cancer-specific survival) deriving from the addition of androgen deprivation to dose-escalated radiotherapy in 1044 patients treated for intermediate or high-risk prostate cancer. In the already cited analysis relative to 104 Belgian patients treated with high-dose IMRT, the addition of androgen deprivation did not influence bRFS [12] .
A possible role for pelvis irradiation?
When retrospectively analyzing the clinical outcome of 55 node-negative (on a median of 6.7 removed pelvic lymph-nodes) high-risk patients, Goldner et al. [18] reported a 4-year bRFS of 58% in patients with an estimated risk of pelvic lymph-nodal involvement of at least 15% according to the Roach formula [2/3 PSA þ (Gleason score -6) Â 10] as compared with 100% in those whose risk was less than 15% (P ¼ 0.004). Although supported only by a small-sized retrospective series, the hypothesis of microscopic pelvic lymph-nodal metastases in patients believed to be node-negative is intriguing.
Accordingly, occult lymph-node metastases were found in 23% of patients candidate to salvage irradiation previously believed to be node-negative and submitted to superparamagnetic lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) [19 ] . These findings raise the question of a possible clinical benefit deriving from the prophylactic irradiation of the pelvic lymph-nodal area (PLNA) in selected patients candidate to postoperative setting, as previously reported by Spiotto et al. [20] . As previously mentioned, the phase III RTOG 0534 trial is evaluating the possible benefit deriving from pelvis irradiation in patients candidate to salvage irradiation.
The main obstacle to the diffusion of WPRT is the widespread concern, in the radiation oncologist community, of an excess of both acute and late toxicities deriving from wider irradiation fields.
Toxicity
The concern about morbidity of postoperative radiotherapy is probably the main reason for which urologists do not recommend salvage and, most of all, ART [4] .
Peterson et al. [21] retrospectively analyzed the toxicity profile of 308 patients treated with SRT from 1987 to 2003 at the Mayo Clinic to a median dose of 64.8 Gy. With a median follow-up of 60 months, the 5-year rate of grade 2 late rectal toxicity was extremely low (1.3%), with no grade 3 sequelae and only one case (0.3%) of grade 4 late toxicity. Grade 2 or greater late genitourinary toxicities occurred in 8% of patients, with 5% of urethral and 3% of bladder complications. These results are consistent with most of the retrospective analyses published to date, in which the radiation doses delivered to the prostatic bed were in the range of 60-66 Gy. If delivered with modern radiotherapy techniques such as IMRT, higher radiation doses can be delivered with a more than acceptable toxicity profile.
In the series of Ost et al. relative to adjuvant IMRT at 74 Gy, the crude incidence of acute gastrointestinal grade 2 toxicity (mainly diarrhea and increased frequency) was 22%, with no cases of grade 3-4 events.
Owing to the well known linear relationship between radiation doses and risk of genitourinary side-effects, the acute genitourinary profile was slightly worse, with a crude incidence of grade 2 and 3 acute genitourinary events of 26 and 8%, respectively. Late toxicity profile was similar, with 7 and 0% of late gastrointestinal sequelae, and 22 and 4% of late grade 2 and 3, respectively, genitourinary complications.
IMRT techniques led to a significant reduction in upper (intestinal) and lower (proctitis) gastrointestinal toxicity when the pelvic nodal area is irradiated. Alongi et al. [22] retrospectively analyzed 172 patients who received prophylactic PLNA irradiation as part of postoperative radiotherapy. Eighty-one were treated with tridimensional conformal radiotherapy (3DCRT), whereas the remaining 91 were treated with two different IMRT techniques (37 with 'step and shoot' IMRT and 54 with helical tomotherapy, HTT). Only 6.6 and 3.3% of patients treated with IMRT developed acute grade at least 2 upper and lower intestinal toxicity, respectively, as compared to 22.2 (P ¼ 0.004) and 8.6% (P ¼ 0.14) of those treated with 3DCRT. When the analysis was restricted to 54 patients treated with HTT, the reduction in the risk of acute grade at least 2 upper (1.8%) and lower (0%) gastrointestinal toxicity was much more evident when compared to 3DCRT (P ¼ 0.001 and 0.03, respectively).
On the contrary, genitourinary acute grade at least 2 toxicity was only marginally reduced by IMRT (6.6%) or HTT (7.4%) when compared to 3DCRT (12.3%).
Differently from rectal toxicity, the risk of severe urinary toxicity has remained almost unchanged over the past 20 years, owing to the need to fully include the bladder neck and the vesicourethral anastomosis in the 'highdose' region. A retrospective analysis of 742 patients treated with either adjuvant (n ¼ 556) or salvage (n ¼ 186) intent was performed with the aim of investigating clinical factors independently predictive of longterm severe urinary sequelae after postprostatectomy irradiation [23] .
After a median follow-up of 99 months, the 8-year risk of grade at least 2 late genitourinary toxicity (mainly bladder bleeding and incontinence) was 23.9 vs. 23.7%, and that of grade 3 late sequelae (mainly urethral stricture) was 12.2 vs. 10%, in adjuvant and salvage cohorts, respectively.
With respect to grade 3 late sequelae, patients submitted to SRT behaved more like those receiving radical treatment, with age more than 71 years and radiotherapy doses more than 72 Gy resulting in a worse toxicity profile. In the adjuvant setting, on the contrary, a higher rate of grade 3 late toxicities was recorded in younger ( 62 years) and hypertensive patients. The cause of this latter correlation is currently unclear and deserves further investigation.
Conclusion
Early, high-dose SRT in the case of BCR after radical prostatectomy may provide long-term biochemical control comparable to that offered by high-dose ART delivered to all high-risk patients. This hypothesis should be confirmed by prospective randomized studies. The role of hormonal therapy and of whole pelvis irradiation in the postoperative setting is being investigated by ongoing large EORTC and RTOG phase III trials in which doses of 70 Gy or less are used. It will be interesting to investigate the possible clinical benefit deriving from combined modality treatment and prophylactic pelvis irradiation also in combination to radiotherapy doses more than 70 Gy.
Modern radiotherapy techniques, such as IMRT and HTT, led to a significant reduction in gastrointestinal, but not genitourinary, toxicity from postprostatectomy irradiation. A better understanding of the ethiopathogenesis of long-term urinary sequelae from adjuvant and SRT is needed to safely deliver doses more than 70 Gy.
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